[go: up one dir, main page]

FR2601014B1 - Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation - Google Patents

Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation

Info

Publication number
FR2601014B1
FR2601014B1 FR878709316A FR8709316A FR2601014B1 FR 2601014 B1 FR2601014 B1 FR 2601014B1 FR 878709316 A FR878709316 A FR 878709316A FR 8709316 A FR8709316 A FR 8709316A FR 2601014 B1 FR2601014 B1 FR 2601014B1
Authority
FR
France
Prior art keywords
preparing
composition
same
crystalline hydrate
oral cephalosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR878709316A
Other languages
English (en)
Other versions
FR2601014A1 (fr
Inventor
Yoshio Hamashima
Kyoji Minami
Kyozo Kawata
Teruo Sakamoto
Toyohiko Takeda
Yusuke Suzuki
Masanori Tujikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61156954A external-priority patent/JP2544113B2/ja
Priority claimed from JP21626086A external-priority patent/JPH0717651B2/ja
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of FR2601014A1 publication Critical patent/FR2601014A1/fr
Application granted granted Critical
Publication of FR2601014B1 publication Critical patent/FR2601014B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
FR878709316A 1986-07-02 1987-07-01 Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation Expired - Lifetime FR2601014B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61156954A JP2544113B2 (ja) 1986-07-02 1986-07-02 安定なカプセル製剤
JP21626086A JPH0717651B2 (ja) 1986-09-12 1986-09-12 経口投与用セフアロスポリン水和物結晶

Publications (2)

Publication Number Publication Date
FR2601014A1 FR2601014A1 (fr) 1988-01-08
FR2601014B1 true FR2601014B1 (fr) 1990-09-14

Family

ID=26484565

Family Applications (1)

Application Number Title Priority Date Filing Date
FR878709316A Expired - Lifetime FR2601014B1 (fr) 1986-07-02 1987-07-01 Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation

Country Status (27)

Country Link
US (2) US4812561A (fr)
KR (1) KR950005302B1 (fr)
CN (1) CN1015106B (fr)
AR (1) AR243893A1 (fr)
AT (1) AT392472B (fr)
AU (1) AU594167B2 (fr)
BE (1) BE1001691A4 (fr)
CA (1) CA1283405C (fr)
CH (1) CH672788A5 (fr)
DE (1) DE3721913A1 (fr)
DK (1) DK161080C (fr)
ES (2) ES2004952A6 (fr)
FI (1) FI89052C (fr)
FR (1) FR2601014B1 (fr)
GB (1) GB2192183B (fr)
GR (1) GR871014B (fr)
HK (1) HK47893A (fr)
HU (1) HU200777B (fr)
IE (1) IE59613B1 (fr)
IL (1) IL83059A (fr)
IT (1) IT1211469B (fr)
NL (1) NL193136C (fr)
NO (1) NO170889C (fr)
NZ (1) NZ220764A (fr)
PL (1) PL159180B1 (fr)
RU (1) RU1829932C (fr)
SE (1) SE466257B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
NZ252433A (en) * 1992-04-30 1996-07-26 Schering Corp Preparation of a dry hydrated cephalosporin powder formulation which is resistant to air oxidation and dehydration by mixing the drug with dry excipients and filling into a sealable storage container
EP1860127B1 (fr) * 1998-10-27 2011-01-12 Westlake Longview Corporation Procédé pour la polymérisation d'oléfines, polyéthylènes et films et articles fabriqués à partir de ceux-ci
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AT412213B (de) * 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
EP1648415A4 (fr) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Produit antibiotique, son utilisation et sa formulation
CA2533358C (fr) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation associees
EP1648407A4 (fr) * 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc Produit antibiotique, utilisation et formulation correspondantes
US8758820B2 (en) * 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
CA2535398C (fr) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotique, utilisation et formulation associees
CA2535780A1 (fr) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Produit antibiotique, son utilisation et sa formulation
EP1663169A4 (fr) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotique, son utilisation et sa formulation
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
WO2006014427A1 (fr) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Comprimé pour distribution par impulsion
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
MX2009006877A (es) 2006-12-22 2009-09-28 Schering Corp Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
EP2064181A1 (fr) * 2006-12-22 2009-06-03 Schering Corporation Dérivés condensés à 4,5 noyaux destinés au traitement ou à la prévention du vhc et des infections virales associées
EP2064180B1 (fr) 2006-12-22 2016-07-13 Merck Sharp & Dohme Corp. Dérivés indoliques condensés en positions 4 et 5 utilisés pour le traitement ou la prévention des infections par le vhc et autre infections virales associées
AU2008295484B2 (en) * 2007-08-29 2013-09-26 Merck Sharp & Dohme Llc Substituted indole derivatives and methods of use thereof
EP2197842B1 (fr) * 2007-08-29 2012-05-23 Schering Corporation Dérivés d'indole substitués en 2 et 3 pour traiter des infections virales
CN101842374A (zh) * 2007-08-29 2010-09-22 先灵公司 用于治疗病毒感染的2，3-取代的氮杂吲哚衍生物
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CN102317285A (zh) * 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
CA2727620A1 (fr) * 2008-06-13 2009-12-17 Schering Corporation Derives d'indole tricycliques et procedes d'utilisation de ceux-ci
EP2326628A1 (fr) 2008-08-20 2011-06-01 Schering Corporation Dérivés de pyridine et pyrimidine substituées par azo et leur utilisation dans le traitement d'infections virales
EP2326627A1 (fr) 2008-08-20 2011-06-01 Schering Corporation Dérivés de pyridine et pyrimidine substituées et leur utilisation dans le traitement d'infections virales
EP2331511A1 (fr) 2008-08-20 2011-06-15 Schering Corporation Dérivés de pyridine et de pyrimidine à substitution éthylyle et leur utilisation dans le traitement d infections virales
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
LT2451445T (lt) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas
WO2011066241A1 (fr) 2009-11-25 2011-06-03 Schering Corporation Composés tricycliques fusionnés et leurs dérivés utiles pour le traitement de maladies virales
WO2011087740A1 (fr) 2009-12-22 2011-07-21 Schering Corporation Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
EP2536410B1 (fr) 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Derives de pyrimidine substitues et leur utilisation dans le traitement d'infections virales
JP2013522202A (ja) 2010-03-09 2013-06-13 メルク・シャープ・エンド・ドーム・コーポレイション 縮合三環式シリル化合物およびウイルス疾患の治療のためのその使用方法
WO2011139253A2 (fr) 2010-05-04 2011-11-10 Mahmut Bilgic Compositions pharmaceutiques comprenant du ceftibutène
EP2598149A4 (fr) 2010-07-26 2014-09-10 Merck Sharp & Dohme Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
WO2012050848A1 (fr) 2010-09-29 2012-04-19 Schering Corporation Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
WO2012142075A1 (fr) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033899A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
WO2013033901A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033900A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013039876A1 (fr) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales
EP2833874A1 (fr) * 2012-04-04 2015-02-11 Mahmut Bilgic Formulations de capsule comprenant du ceftibutène
EP2815743A1 (fr) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations comprenant du ceftibutène
WO2015065817A1 (fr) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103948932B (zh) * 2014-04-17 2016-03-16 海南日中天制药有限公司 一种头孢克肟组合物及其制备方法
EP3031450A1 (fr) 2014-12-12 2016-06-15 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions de gélules de ceftibutène
WO2017197371A1 (fr) 2016-05-13 2017-11-16 Aeromics, Inc. Cristaux
CN106397455B (zh) * 2016-08-30 2018-08-31 山东罗欣药业集团恒欣药业有限公司 一种抗感染药物头孢布烯晶体化合物及其组合物
CN106397454B (zh) * 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
CN106432271A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106397457A (zh) * 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432270A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432272A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
WO2023278945A1 (fr) * 2021-07-01 2023-01-05 Qpex Biopharma, Inc. Formes cristallines de ceftibuten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819620A (en) * 1972-06-01 1974-06-25 Squibb & Sons Inc 7-(d-alpha-amino-1,4-cyclohexadien-1-ylacet-amido)desacetoxycephalosporanic acid dihydrate
JPS5726692A (en) * 1980-07-22 1982-02-12 Fujisawa Pharmaceut Co Ltd Preparation of stable crystal of salt of ceftizoxime
DE3037997A1 (de) * 1980-10-08 1982-05-13 Bayer Ag (beta) -lactamantibiotika, verfahren zu deren herstellung sowie sie enthaltende mittel
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters

Also Published As

Publication number Publication date
GB2192183A (en) 1988-01-06
AT392472B (de) 1991-04-10
IT1211469B (it) 1989-11-03
HK47893A (en) 1993-05-27
IE59613B1 (en) 1994-03-09
CN1015106B (zh) 1991-12-18
NL8701507A (nl) 1988-02-01
NO872729D0 (no) 1987-06-30
IL83059A0 (en) 1987-12-31
RU1829932C (ru) 1993-07-23
GB8715064D0 (en) 1987-08-05
PL159180B1 (pl) 1992-11-30
FI89052C (fi) 1993-08-10
NL193136B (nl) 1998-08-03
SE8702705D0 (sv) 1987-06-30
GR871014B (en) 1987-11-02
FI872903A0 (fi) 1987-07-01
FI872903L (fi) 1988-01-03
ES2008759A6 (es) 1989-08-01
CN87105009A (zh) 1988-03-23
BE1001691A4 (fr) 1990-02-13
IT8767566A0 (it) 1987-07-01
IE871738L (en) 1988-01-02
NO170889B (no) 1992-09-14
NO872729L (no) 1988-01-04
NL193136C (nl) 1998-12-04
DK161080C (da) 1991-11-11
CA1283405C (fr) 1991-04-23
HU200777B (en) 1990-08-28
FI89052B (fi) 1993-04-30
GB2192183B (en) 1990-05-16
ES2004952A6 (es) 1989-02-16
HUT44257A (en) 1988-02-29
FR2601014A1 (fr) 1988-01-08
IL83059A (en) 1992-03-29
PL266567A1 (en) 1988-07-21
DK336487D0 (da) 1987-06-30
KR950005302B1 (ko) 1995-05-23
DK336487A (da) 1988-01-03
KR880001670A (ko) 1988-04-26
ATA165887A (de) 1990-09-15
US4933443A (en) 1990-06-12
SE466257B (sv) 1992-01-20
SE8702705L (sv) 1988-01-03
DE3721913A1 (de) 1988-01-07
DK161080B (da) 1991-05-27
AR243893A1 (es) 1993-09-30
AU7504087A (en) 1988-01-07
NZ220764A (en) 1989-09-27
NO170889C (no) 1992-12-23
AU594167B2 (en) 1990-03-01
US4812561A (en) 1989-03-14
CH672788A5 (fr) 1989-12-29

Similar Documents

Publication Publication Date Title
FR2601014B1 (fr) Hydrate cristallin de cephalosporine orale, sa composition et son procede de preparation
HUT44553A (en) Process for preparing crystalline carbapenem derivatives
PT82794A (en) Process for preparing 3-phenyl-4-cyanopyrrole derivatives useful as microbicides
PT86309A (en) Process for the preparation of substituted basic 2-aminotetralins
NO176125C (no) Fremgangsmåte for fremstilling av granulater for orale multipartikkelblandinger med kontrollert frigjöring
PT86800A (pt) Process for the preparation of erythromycin derivatives
FI90942B (fi) Kiinteän, kiteisen nedokromiilinatriumin valmistusmenetelmä
NO170581C (no) Fremgangsmaate for fremstilling av vannfritt, krystallinsknatriumsalt av 5-klor-3-(2-tenoyl)-2-oksindol-1-karboksamid
PT81840A (en) Process for the production of cephem derivatives useful as antibacterial agents
GR3017917T3 (en) Crystalline addition salts of cephem compounds and process for their preparation.
AU8213887A (en) Process for the preparation of asbestiform crystalline calcium sodium metaphosphate fiber
PT83812A (en) Process for preparing amorphous benzimidazole derivatives
GB2152497B (en) Process for the preparation of azetidinone derivatives
PT86899A (pt) Process for preparing 27-halo derivatives of ll-f28249 compounds
EP0373216A4 (en) Cephalosporin compounds or their salts, process for their preparation, and parmaceutical compositions
HUT43245A (en) Compounds containing as active substance hindering pollen formation derivatives of pirasole and process for production of the active substance
PT88465A (pt) Process for the preparation of macrolide compounds
PT88467A (pt) Process for the preparation of macrolide compounds
AU8213787A (en) Process for the preparation of crystalline calcium sodium metaphosphate
IL90635A0 (en) Process for the preparation of quinoline antibacterial compounds
FI92393B (fi) Menetelmä 1,5-bentsotiatsepiinijohdannaisten valmistamiseksi
NO872825L (no) FremgangsmŸte for fremstilling av antibakterielt aktive cefalosporinderivater.
AU1228988A (en) Cephalosporin compounds or their salts, process for their preparation, and pharmaceutical compositions
PT88466A (pt) Process for the preparation of macrolide compounds
ZA886737B (en) Process for the preparation of macrolide compounds